Shanghai Cell Therapy Group Co., Ltd.

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 1
CD19, CD22, and BCMA (tri-antigen)Cell therapy
Systemic Lupus Erythematosus
Phase 1
CD19, CD20, and BCMA (tri-target)Cell therapy
Multiple Myeloma

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.